{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:56:58Z","timestamp":1784091418442,"version":"3.55.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Dr. Norman & Melinda Payson Professorship"},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA242218"],"award-info":[{"award-number":["R01CA242218"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K08CA234394"],"award-info":[{"award-number":["K08CA234394"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA033572"],"award-info":[{"award-number":["P30CA033572"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"publisher","award":["Research Professorship in Breast Cancer Diaparities"],"award-info":[{"award-number":["Research Professorship in Breast Cancer Diaparities"]}],"id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s10549-021-06201-y","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T15:03:34Z","timestamp":1617807814000},"page":"759-768","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Multigene assessment of genetic risk for women for two or more breast cancers"],"prefix":"10.1007","volume":"188","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6714-092X","authenticated-orcid":false,"given":"Jeffrey N.","family":"Weitzel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kidd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Bernhisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Shehayeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Frankel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen R.","family":"Blazer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Turco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bita","family":"Nehoray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"McGreevy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kira","family":"Svirsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystal","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Gardiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Daly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisha","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Saam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Slavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,7]]},"reference":[{"issue":"4","key":"6201_CR1","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1067\/msy.2003.110","volume":"133","author":"AP Polednak","year":"2003","unstructured":"Polednak AP (2003) Bilateral synchronous breast cancer: a population-based study of characteristics, method of detection, and survival. Surgery 133(4):383\u2013389. https:\/\/doi.org\/10.1067\/msy.2003.110","journal-title":"Surgery"},{"issue":"6","key":"6201_CR2","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1002\/cam4.2198","volume":"8","author":"B Pan","year":"2019","unstructured":"Pan B, Xu Y, Zhou YD et al (2019) The prognostic comparison among unilateral, bilateral, synchronous bilateral, and metachronous bilateral breast cancer: a meta-analysis of studies from recent decade (2008\u20132018). Cancer Med 8(6):2908\u20132918. https:\/\/doi.org\/10.1002\/cam4.2198","journal-title":"Cancer Med"},{"issue":"11","key":"6201_CR3","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/jnci\/djt095","volume":"105","author":"N Mavaddat","year":"2013","unstructured":"Mavaddat N, Peock S, Frost D et al (2013) Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 105(11):812\u2013822. https:\/\/doi.org\/10.1093\/jnci\/djt095","journal-title":"J Natl Cancer Inst"},{"issue":"8899","key":"6201_CR4","first-page":"692","volume":"343","author":"D Ford","year":"1994","unstructured":"Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE (1994) Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium Lancet 343(8899):692\u2013695","journal-title":"Breast Cancer Linkage Consortium Lancet"},{"issue":"4","key":"6201_CR5","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1002\/cam4.1376","volume":"7","author":"J Hauke","year":"2018","unstructured":"Hauke J, Horvath J, Gross E et al (2018) Gene panel testing of 5589 BRCA1\/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for hereditary breast and ovarian cancer. Cancer Med 7(4):1349\u20131358. https:\/\/doi.org\/10.1002\/cam4.1376","journal-title":"Cancer Med"},{"issue":"12","key":"6201_CR6","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1038\/s41436-018-0005-9","volume":"20","author":"L Castera","year":"2018","unstructured":"Castera L, Harter V, Muller E et al (2018) Landscape of pathogenic variations in a panel of 34 genes and cancer risk estimation from 5131 HBOC families. Genet Med 20(12):1677\u20131686. https:\/\/doi.org\/10.1038\/s41436-018-0005-9","journal-title":"Genet Med"},{"key":"6201_CR7","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1200\/PO.19.00301","volume":"4","author":"KN Maxwell","year":"2020","unstructured":"Maxwell KN, Wenz BM, Kulkarni A et al (2020) Mutation rates in cancer susceptibility genes in patients with breast cancer with multiple primary cancers. JCO Precis Oncol 4:916\u2013925. https:\/\/doi.org\/10.1200\/PO.19.00301","journal-title":"JCO Precis Oncol"},{"key":"6201_CR8","unstructured":"Daly MB, Pilarski R, Berry M et al. (2020) NCCN Guidelines Version 1.2021 Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic National Comprehensive Cancer Network (NCCN). https:\/\/www.nccn.org\/."},{"key":"6201_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020378","author":"Z Hyder","year":"2020","unstructured":"Hyder Z, Harkness EF, Woodward ER et al (2020) Risk of Contralateral Breast Cancer in Women with and without Pathogenic Variants in BRCA1, BRCA2, and TP53 Genes in Women with Very Early-Onset (<36 Years) Breast Cancer. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers12020378","journal-title":"Cancers (Basel)"},{"issue":"6","key":"6201_CR10","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1158\/0008-5472.CAN-10-3958","volume":"71","author":"S Casadei","year":"2011","unstructured":"Casadei S, Norquist BM, Walsh T et al (2011) Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Can Res 71(6):2222\u20132229. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-3958","journal-title":"Can Res"},{"issue":"6","key":"6201_CR11","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa1400382","volume":"371","author":"AC Antoniou","year":"2014","unstructured":"Antoniou AC, Casadei S, Heikkinen T et al (2014) Breast-cancer risk in families with mutations in PALB2. N Engl J Med 371(6):497\u2013506. https:\/\/doi.org\/10.1056\/NEJMoa1400382","journal-title":"N Engl J Med"},{"issue":"3","key":"6201_CR12","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s10549-012-1993-9","volume":"133","author":"S Masciari","year":"2012","unstructured":"Masciari S, Dillon DA, Rath M et al (2012) Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. Breast Cancer Res Treat 133(3):1125\u20131130. https:\/\/doi.org\/10.1007\/s10549-012-1993-9","journal-title":"Breast Cancer Res Treat"},{"issue":"14","key":"6201_CR13","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1002\/cncr.25876","volume":"117","author":"ZM Xie","year":"2011","unstructured":"Xie ZM, Li LS, Laquet C et al (2011) Germline mutations of the E-cadherin gene in families with inherited invasive lobular breast carcinoma but no diffuse gastric cancer. Cancer 117(14):3112\u20133117. https:\/\/doi.org\/10.1002\/cncr.25876","journal-title":"Cancer"},{"key":"6201_CR14","unstructured":"Daly MB, Pilarski R, Berry MP et al. (2020) NCCN Clinical Practice Guidelines in Oncology: Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic (Version 1.2020). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_screening.pdf. Accessed January 14, 2020"},{"issue":"4","key":"6201_CR15","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.breast.2014.01.015","volume":"23","author":"M Dieterich","year":"2014","unstructured":"Dieterich M, Hartwig F, Stubert J et al (2014) Accompanying DCIS in breast cancer patients with invasive ductal carcinoma is predictive of improved local recurrence-free survival. Breast (Edinburgh, Scotland) 23(4):346\u2013351. https:\/\/doi.org\/10.1016\/j.breast.2014.01.015","journal-title":"Breast (Edinburgh, Scotland)"},{"issue":"1","key":"6201_CR16","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12885-015-1224-y","volume":"15","author":"T Judkins","year":"2015","unstructured":"Judkins T, Leclair B, Bowles K et al (2015) Development and analytical validation of a 25-gene next generation sequencing panel that includes the BRCA1 and BRCA2 genes to assess hereditary cancer risk. BMC Cancer 15(1):215","journal-title":"BMC Cancer"},{"issue":"1","key":"6201_CR17","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12920-019-0587-3","volume":"12","author":"D Mancini-DiNardo","year":"2019","unstructured":"Mancini-DiNardo D, Judkins T, Kidd J et al (2019) Detection of large rearrangements in a hereditary pan-cancer panel using next-generation sequencing. BMC Med Genomics 12(1):138. https:\/\/doi.org\/10.1186\/s12920-019-0587-3","journal-title":"BMC Med Genomics"},{"issue":"5","key":"6201_CR18","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med 17(5):405\u2013424. https:\/\/doi.org\/10.1038\/gim.2015.30","journal-title":"Genet Med"},{"issue":"3","key":"6201_CR19","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/cge.12315","volume":"86","author":"JM Eggington","year":"2014","unstructured":"Eggington JM, Bowles KR, Moyes K et al (2014) A comprehensive laboratory-based program for classification of variants of uncertain significance in hereditary cancer genes. Clin Genet 86(3):229\u2013237. https:\/\/doi.org\/10.1111\/cge.12315","journal-title":"Clin Genet"},{"key":"6201_CR20","doi-asserted-by":"publisher","DOI":"10.1200\/PO.20.00020","author":"L Esterling","year":"2020","unstructured":"Esterling L, Wijayatunge R, Brown K et al (2020) Impact of a cancer gene variant reclassification program over a 20-year period. JCO Precis Oncol. https:\/\/doi.org\/10.1200\/PO.20.00020","journal-title":"JCO Precis Oncol"},{"key":"6201_CR21","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-20-0448","author":"MJ Hall","year":"2021","unstructured":"Hall MJ, Bernhisel R, Hughes E et al (2021) Germline pathogenic variants in the Ataxia Telangiectasia Mutated (ATM) gene are associated with high and moderate risks for multiple cancers. AACR Cancer Prevent Res. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-20-0448","journal-title":"AACR Cancer Prevent Res"},{"key":"6201_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/po.16.00066","volume":"1","author":"AW Kurian","year":"2017","unstructured":"Kurian AW, Hughes E, Handorf EA et al (2017) Breast and ovarian cancer penetrance estimates derived from germline multiple-gene sequencing results in women. JCO Precis Oncol 1:1\u201312. https:\/\/doi.org\/10.1200\/po.16.00066","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"6201_CR23","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s10549-020-05543-3","volume":"180","author":"I Rainville","year":"2020","unstructured":"Rainville I, Hatcher S, Rosenthal E et al (2020) High risk of breast cancer in women with biallelic pathogenic variants in CHEK2. Breast Cancer Res Treat 180(2):503\u2013509. https:\/\/doi.org\/10.1007\/s10549-020-05543-3","journal-title":"Breast Cancer Res Treat"},{"key":"6201_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/tbj.13762","author":"J Corredor","year":"2020","unstructured":"Corredor J, Woodson AH, Gutierrez Barrera A, Arun B (2020) Multigene panel testing results in patients with multiple breast cancer primaries. Breast J. https:\/\/doi.org\/10.1111\/tbj.13762","journal-title":"Breast J"},{"key":"6201_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/po.16.00021","volume":"1","author":"K Lowstuter","year":"2017","unstructured":"Lowstuter K, Espenschied CR, Sturgeon D et al (2017) Unexpected CDH1 mutations identified on multigene panels pose clinical management challenges. JCO Precis Oncol 1:1\u201312. https:\/\/doi.org\/10.1200\/po.16.00021","journal-title":"JCO Precis Oncol"},{"issue":"8","key":"6201_CR26","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/gim.2017.196","volume":"20","author":"JN Weitzel","year":"2018","unstructured":"Weitzel JN, Chao EC, Nehoray B et al (2018) Somatic TP53 variants frequently confound germ-line testing results. Genet Med 20(8):809\u2013816. https:\/\/doi.org\/10.1038\/gim.2017.196","journal-title":"Genet Med"},{"issue":"8","key":"6201_CR27","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1093\/jnci\/djy001","volume":"110","author":"HQ Rana","year":"2018","unstructured":"Rana HQ, Gelman R, LaDuca H et al (2018) Differences in TP53 mutation carrier phenotypes emerge from panel-based testing. J Natl Cancer Inst 110(8):863\u2013870. https:\/\/doi.org\/10.1093\/jnci\/djy001","journal-title":"J Natl Cancer Inst"},{"key":"6201_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-017-0024-8","author":"TP Slavin","year":"2017","unstructured":"Slavin TP, Maxwell KN, Lilyquist J et al (2017) The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. NPJ Breast Cancer. https:\/\/doi.org\/10.1038\/s41523-017-0024-8","journal-title":"NPJ Breast Cancer"},{"key":"6201_CR29","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.cancergen.2017.09.003","volume":"218\u2013219","author":"ET Rosenthal","year":"2017","unstructured":"Rosenthal ET, Bernhisel R, Brown K, Kidd J, Manley S (2017) Clinical testing with a panel of 25 genes associated with increased cancer risk results in a significant increase in clinically significant findings across a broad range of cancer histories. Cancer Genet 218\u2013219:58\u201368. https:\/\/doi.org\/10.1016\/j.cancergen.2017.09.003","journal-title":"Cancer Genet"},{"issue":"35","key":"6201_CR30","doi-asserted-by":"publisher","first-page":"4308","DOI":"10.1200\/JCO.2012.42.7336","volume":"30","author":"M Weischer","year":"2012","unstructured":"Weischer M, Nordestgaard BG, Pharoah P et al (2012) CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. J Clin Oncol 30(35):4308\u20134316","journal-title":"J Clin Oncol"},{"issue":"38","key":"6201_CR31","doi-asserted-by":"publisher","first-page":"6445","DOI":"10.1038\/sj.onc.1207714","volume":"23","author":"R Nagy","year":"2004","unstructured":"Nagy R, Sweet K, Eng C (2004) Highly penetrant hereditary cancer syndromes. Oncogene 23(38):6445\u20136470. https:\/\/doi.org\/10.1038\/sj.onc.1207714","journal-title":"Oncogene"},{"issue":"2","key":"6201_CR32","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/ijc.26398","volume":"131","author":"I Kluijt","year":"2012","unstructured":"Kluijt I, Siemerink EJ, Ausems MG et al (2012) CDH1-related hereditary diffuse gastric cancer syndrome: clinical variations and implications for counseling. Int J Cancer J int du Cancer 131(2):367\u2013376. https:\/\/doi.org\/10.1002\/ijc.26398","journal-title":"Int J Cancer J int du Cancer"},{"key":"6201_CR33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01907","author":"X Yang","year":"2019","unstructured":"Yang X, Leslie G, Doroszuk A et al (2019) Cancer risks associated with germline palb2 pathogenic variants an international study of 524 families. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.19.01907","journal-title":"J Clin Oncol"},{"key":"6201_CR34","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1200\/PO.19.00271","volume":"4","author":"JR Stoll","year":"2020","unstructured":"Stoll JR, Cummings E, Willmott S, Bernhisel J, Kupfer R (2020) No evidence of increased risk of breast cancer in women with Lynch syndrome identifed by multigene panel testing. JCO Precis Oncol 4:51\u201360","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"6201_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41436-019-0596-9","volume":"22","author":"M Dominguez-Valentin","year":"2020","unstructured":"Dominguez-Valentin M, Sampson JR, Seppala TT et al (2020) Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the prospective Lynch syndrome database. Genet Med 22(1):15\u201325. https:\/\/doi.org\/10.1038\/s41436-019-0596-9","journal-title":"Genet Med"},{"issue":"9","key":"6201_CR36","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nrclinonc.2016.90","volume":"13","author":"N Tung","year":"2016","unstructured":"Tung N, Domchek SM, Stadler Z et al (2016) Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nat Rev Clin Oncol 13(9):581\u2013588. https:\/\/doi.org\/10.1038\/nrclinonc.2016.90","journal-title":"Nat Rev Clin Oncol"},{"issue":"23","key":"6201_CR37","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1056\/NEJMsr1501341","volume":"372","author":"DF Easton","year":"2015","unstructured":"Easton DF, Pharoah PD, Antoniou AC et al (2015) Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med 372(23):2243\u20132257","journal-title":"N Engl J Med"},{"issue":"9","key":"6201_CR38","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1001\/jamaoncol.2017.0424","volume":"3","author":"FJ Couch","year":"2017","unstructured":"Couch FJ, Shimelis H, Hu C et al (2017) Associations between cancer predisposition testing panel genes and breast cancer. JAMA Oncol 3(9):1190\u20131196. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0424","journal-title":"JAMA Oncol"},{"issue":"15","key":"6201_CR39","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1200\/JCO.18.01854","volume":"37","author":"AW Kurian","year":"2019","unstructured":"Kurian AW, Ward KC, Howlader N et al (2019) Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients. J Clin Oncol 37(15):1305\u20131315. https:\/\/doi.org\/10.1200\/JCO.18.01854","journal-title":"J Clin Oncol"},{"issue":"3","key":"6201_CR40","doi-asserted-by":"publisher","first-page":"e1003212","DOI":"10.1371\/journal.pgen.1003212","volume":"9","author":"FJ Couch","year":"2013","unstructured":"Couch FJ, Wang X, McGuffog L et al (2013) Genome-wide association study in brca1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet 9(3):e1003212. https:\/\/doi.org\/10.1371\/journal.pgen.1003212","journal-title":"PLoS Genet"},{"issue":"6","key":"6201_CR41","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1086\/522611","volume":"81","author":"AC Antoniou","year":"2007","unstructured":"Antoniou AC, Sinilnikova OM, Simard J et al (2007) RAD51 135G\u2013>C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet 81(6):1186\u20131200. https:\/\/doi.org\/10.1086\/522611","journal-title":"Am J Hum Genet"},{"issue":"14","key":"6201_CR42","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1093\/hmg\/ddq174","volume":"19","author":"X Wang","year":"2010","unstructured":"Wang X, Pankratz VS, Fredericksen Z et al (2010) Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Hum Mol Genet 19(14):2886\u20132897. https:\/\/doi.org\/10.1093\/hmg\/ddq174","journal-title":"Hum Mol Genet"},{"issue":"23","key":"6201_CR43","doi-asserted-by":"publisher","first-page":"9742","DOI":"10.1158\/0008-5472.CAN-10-1907","volume":"70","author":"AC Antoniou","year":"2010","unstructured":"Antoniou AC, Beesley J, McGuffog L et al (2010) Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res 70(23):9742\u20139754. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-1907","journal-title":"Cancer Res"},{"issue":"1","key":"6201_CR44","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ajhg.2018.11.002","volume":"104","author":"N Mavaddat","year":"2019","unstructured":"Mavaddat N, Michailidou K, Dennis J et al (2019) Polygenic risk scores for prediction of breast cancer and breast cancer subtypes. The American Journal of Human Genetics 104(1):21\u201334. https:\/\/doi.org\/10.1016\/j.ajhg.2018.11.002","journal-title":"The American Journal of Human Genetics"},{"issue":"7","key":"6201_CR45","doi-asserted-by":"publisher","first-page":"e208501","DOI":"10.1001\/jamanetworkopen.2020.8501","volume":"3","author":"S Gallagher","year":"2020","unstructured":"Gallagher S, Hughes E, Wagner S, Tshiaba P, Rosenthal R, Roa BB, Kurian AW, Domchek SM, Garber J, Lancaster J, Weitzel JN, Gutin A, Lanchbury JS, Robson M (2020) Association of a polygenic risk score with breast cancer among women carriers of high and moderate risk breast cancer genes. JAMA Netw Open 3(7):e208501","journal-title":"JAMA Netw Open"},{"key":"6201_CR46","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx051","author":"ME Robson","year":"2017","unstructured":"Robson ME, Reiner AS, Brooks JD et al (2017) Association of common genetic variants with contralateral breast cancer risk in the WECARE study. J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djx051","journal-title":"J Natl Cancer Inst"},{"issue":"35","key":"6201_CR47","doi-asserted-by":"publisher","first-page":"4330","DOI":"10.1200\/JCO.2012.41.7469","volume":"30","author":"S Sawyer","year":"2012","unstructured":"Sawyer S, Mitchell G, McKinley J et al (2012) A role for common genomic variants in the assessment of familial breast cancer. J Clin Oncol 30(35):4330\u20134336. https:\/\/doi.org\/10.1200\/JCO.2012.41.7469","journal-title":"J Clin Oncol"},{"key":"6201_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2020.09.001","author":"I Kramer","year":"2020","unstructured":"Kramer I, Hooning MJ, Mavaddat N et al (2020) Breast cancer polygenic risk score and contralateral breast cancer risk. Am J Hum Genet. https:\/\/doi.org\/10.1016\/j.ajhg.2020.09.001","journal-title":"Am J Hum Genet"},{"key":"6201_CR49","volume-title":"Modern epidemiology","author":"KJ Rothman","year":"2008","unstructured":"Rothman KJ, Greenland S, Lash T (2008) Modern epidemiology, vol 3. Lippincott Williams & Wilkins, Philadelphia, PA"},{"key":"6201_CR50","unstructured":"RajamaniI S (2016) Eliminating bias in cancer risk estimates: a simulation study. Dissertation, University of Utah"},{"key":"6201_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2020.11.008","author":"Y Chavarri-Guerra","year":"2020","unstructured":"Chavarri-Guerra Y, Marcum CA, Hendricks CB, Wilbur D, Cescon T, Hake C, Abugattas J, Rodriguez Y, Villarreal-Garza C, Yang K, Cervantes A, Sand S, Castillo D, Herzog J, Mokhnatkin J, Sedrak MS, Soto-Perez-de-Celis E, Weitzel JN (2020) Breast cancer associated pathogenic variants among women 61years and older with triple negative breast cancer. J Geriat Oncol. https:\/\/doi.org\/10.1016\/j.jgo.2020.11.008","journal-title":"J Geriat Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06201-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-021-06201-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06201-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T18:09:33Z","timestamp":1625940573000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-021-06201-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,7]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["6201"],"URL":"https:\/\/doi.org\/10.1007\/s10549-021-06201-y","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,7]]},"assertion":[{"value":"3 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors JK, RB, DT, KM, KS, KB, AG, EH, SC, JS and TS were employees of Myriad Genetics at the time of manuscript preparation and had stock options. JNW received speaker fees from AstraZeneca. No other authors have any conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All individuals provided consent for clinical testing, and testing data were de-identified for analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All individuals provided consent for clinical testing, and testing data were de-identified for analysis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors have provided consent for the manuscript to be submitted for review and publication in the journal <i>Breast Cancer Research and Treatment<\/i>.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}